Spirox Stock

Spirox Liabilities

The The Liabilities of Spirox (3055.TW) as of Aug 7, 2026 is 341.59 M TWD. In the previous year, The Liabilities was 464.92 M TWD — a change of -26.53% (lower).

Liabilities

341.59 MTWD

YoY

-26.53%

Last updated:

In 2026, Spirox's total liabilities amounted to 341.59 M TWD, a -26.53% difference from the 464.92 M TWD total liabilities in the previous year.

Access this data via the Eulerpool API

Spirox Stock analysis

What does Spirox do? The Spirox Corporation is a company that was founded in 2007 and is headquartered in Menlo Park, California. The company operates in the medical technology industry and specializes in the development of products for nasal breathing. The mission of Spirox is to help people who have difficulty breathing through their nose. The company has recognized that many people have difficulty breathing through their nose due to congestion or other issues. Breathing through the mouth, however, can lead to a range of health problems such as dry mouth, sleep apnea, and respiratory infections. Therefore, Spirox has set out to develop innovative solutions to facilitate nasal breathing. Spirox's products include both implantable and non-implantable solutions. The company has a small but effective product portfolio consisting of two products: the Latera Nasal Stent and the AeroForm Nasal Stent. The Latera Nasal Stent is used to permanently open the nasal passages and facilitate breathing. The placement of the stent is a minimally invasive procedure that is typically performed on an outpatient basis. The Latera Nasal Stent is inserted and secured in the nasal wings to allow for better airflow through the nostrils. The stent is made of polydioxanone (PDO), a biocompatible polymer fiber that is absorbed by the body. Spirox's second product, the AeroForm Nasal Stent, is a non-implantable nasal stent used for temporary relief of nasal breathing. The AeroForm is a soft stent made of a flexible polymer material. It is inserted into the nasal passages and forms a gentle expansion to facilitate nasal breathing. As a company, Spirox focuses on collaboration with specialists and clinics to ensure that their products have high success rates. The company has established a partnership with the American Academy of Otolaryngology - Head and Neck Surgery (AAO-HNS) to advance scientific research and development in the nasal breathing industry. Spirox is led by experienced executives from the medical technology industry. The CEO, Duke Rohlen, has over 20 years of experience in leading medical technology companies such as Inspire Medical Systems and CV Ingenuity. The board team also includes Elektra Papadopoulos as Chair of the Board, who has worked at Hologic and Boston Scientific, among others. Although Spirox is a relatively small company, it has already received several awards. In 2017, the company was awarded the Red Herring Top 100 North America Award, which recognizes companies that are leading in the innovation industry. Overall, Spirox is an emerging company in the medical technology industry that offers innovative solutions to facilitate nasal breathing. Through collaboration with doctors and clinics and a focus on scientific research, the company aims to improve the success and effectiveness of its products. Spirox is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Spirox's Liabilities

Spirox's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Spirox's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Spirox's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Spirox's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Spirox’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Spirox stock

The Liabilities of Spirox is 341.59 M TWD in 2026.

The Liabilities of Spirox changed from 464.92 M TWD to 341.59 M TWD, representing a -26.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Spirox since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Spirox historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Spirox

All Key Metrics — Spirox